MX2022003101A - Metodos de tratamiento de enfermedades oculares. - Google Patents

Metodos de tratamiento de enfermedades oculares.

Info

Publication number
MX2022003101A
MX2022003101A MX2022003101A MX2022003101A MX2022003101A MX 2022003101 A MX2022003101 A MX 2022003101A MX 2022003101 A MX2022003101 A MX 2022003101A MX 2022003101 A MX2022003101 A MX 2022003101A MX 2022003101 A MX2022003101 A MX 2022003101A
Authority
MX
Mexico
Prior art keywords
treatment
methods
eye diseases
diseases
eye
Prior art date
Application number
MX2022003101A
Other languages
English (en)
Spanish (es)
Inventor
Margarita Gekkieva
Philippe Maria Clotaire Margaron
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2022003101A publication Critical patent/MX2022003101A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2022003101A 2019-09-13 2020-09-11 Metodos de tratamiento de enfermedades oculares. MX2022003101A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962899892P 2019-09-13 2019-09-13
US202062971405P 2020-02-07 2020-02-07
PCT/IB2020/058459 WO2021048806A1 (en) 2019-09-13 2020-09-11 Methods for treating ocular diseases

Publications (1)

Publication Number Publication Date
MX2022003101A true MX2022003101A (es) 2022-04-06

Family

ID=72521675

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022003101A MX2022003101A (es) 2019-09-13 2020-09-11 Metodos de tratamiento de enfermedades oculares.

Country Status (11)

Country Link
US (1) US20240052024A1 (https=)
EP (1) EP4028128A1 (https=)
JP (1) JP7828274B2 (https=)
KR (1) KR20220062279A (https=)
CN (1) CN114375201A (https=)
AU (1) AU2020347575A1 (https=)
CA (1) CA3149706A1 (https=)
IL (1) IL289436A (https=)
MX (1) MX2022003101A (https=)
TW (1) TW202116802A (https=)
WO (1) WO2021048806A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3886946A1 (en) 2019-06-05 2021-10-06 Regeneron Pharmaceuticals, Inc. Devices and methods for precision dose delivery
TW202337496A (zh) * 2022-03-17 2023-10-01 瑞士商諾華公司 治療新生血管性年齡相關性黃斑點退化之方法
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1802334E (pt) 2004-10-21 2012-11-28 Genentech Inc Método para tratamento de doenças neovasculares intraoculares
BRPI0914251B1 (pt) 2008-06-25 2022-07-19 Novartis Ag Imunoligante recombinante, seu fragmento de ligação ao antígeno, uso dos mesmos, e composição

Also Published As

Publication number Publication date
JP2022547537A (ja) 2022-11-14
CA3149706A1 (en) 2021-03-18
WO2021048806A1 (en) 2021-03-18
TW202116802A (zh) 2021-05-01
JP7828274B2 (ja) 2026-03-11
AU2020347575A1 (en) 2022-03-17
US20240052024A1 (en) 2024-02-15
CN114375201A (zh) 2022-04-19
EP4028128A1 (en) 2022-07-20
IL289436A (en) 2022-02-01
KR20220062279A (ko) 2022-05-16

Similar Documents

Publication Publication Date Title
MX2020009140A (es) Metodos para el tratamiento de enfermedades oculares.
MX2022003101A (es) Metodos de tratamiento de enfermedades oculares.
EA200901211A1 (ru) Антигены белка с5 и их применение
EP4491229A3 (en) Coding rna administered into the suprachoroidal space in the treatment of ophtalmic diseases
CY1125325T1 (el) Χρηση υδροχλωρικης πιλοκαρπινης για τη θεραπεια της πρεσβυωπιας
MX2021006768A (es) Metodos para tratar enfermedades oculares.
EA202091846A1 (ru) Соединения с активностью, индуцирующей ферроптоз, и способы их применения
MX386832B (es) Inhibidor angptl8 e inhibidor angptl3 para usarse en el tratamiento de hiperlipidemia.
JOP20210166A1 (ar) علاج الصداع الناتج عن فرط استعمال الأدوية باستخدام أجسام مضادة لـcgrp أو أجسام مضادة لـcgrp-r
MX391627B (es) Aplicación cuantitativa periorbital de fármacos oftalmológicos.
EA201892265A1 (ru) Способы лечения офтальмологических заболеваний
CO2022010592A2 (es) Métodos de tratamiento de la esplenomegalia
CO2024007361A2 (es) Anticuerpos anti-c3 y fragmentos de unión al antígeno de estos y sus usos para tratar enfermedades oftálmicas u oculares
WO2019043649A3 (en) ANGIO -3 FOR THE TREATMENT OF RETINAL ANGIOGENIC DISEASES
RU2014140797A (ru) Способ лечения кератоконуса и миопии высокой степени с тонкой роговицей
MX2022012632A (es) Uso de inhibidores del bromodominio para el tratamiento de la enfermedad de huntington.
JOP20210217A1 (ar) طرق لعلاج ألم سطح عين
BR112018068625A2 (pt) métodos de tratamento ou prevenção de doença de enxerto contra hospedeiro
EA202192961A1 (ru) Ребамипид для применения в профилактике и/или лечении синуклеинопатий
EP4362923A4 (en) Pharmacological agents for preventing and treating cataracts and presbyopia eye diseases
AR116024A1 (es) Métodos de tratamiento de enfermedades neurodegenerativas
MX2024007900A (es) Tratamiento de enfermedades renales con inhibidores de la angiopoyetina tipo 3 (angptl3).
EA201491048A1 (ru) Соединения двухцепочечных рнк к casp2 и их применение
SA522432069B1 (ar) Nrp1a أجسام مضادة لـ واستخداماتها لعلاج العين أو أمراض العين
EP4284507A4 (en) Methods of treating ocular fibrotic pathologies